Plasma levels of cyclic GMP, immune parameters and depressive status during interferon therapy. A prospective study in Japan

Neuropsychobiology. 1997;35(3):128-31. doi: 10.1159/000119333.

Abstract

In this report, we investigated the relationship between depressive symptoms and plasma interferon (IFN)-alpha-like immunoreactivity, cyclic GMP (cGMP) and soluble interleukin-2 receptor (sIL-2R) levels during IFN therapy. An altered mood state was observed in 5 of 26 patients. IFN-alpha-like immunoreactivity in the depressed group tended to be elevated. cGMP levels of depressed patients were significantly greater than those of control subjects before and 6 weeks after IFN therapy. However, sIL-2R levels were not different between the two groups. These results suggest that a number of patients suffered from depression during IFN therapy and that patients had greater concentrations of cGMP levels.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cyclic GMP / blood*
  • Depressive Disorder / chemically induced*
  • Depressive Disorder / metabolism
  • Humans
  • Immunohistochemistry
  • Interferons / adverse effects*
  • Japan
  • Male
  • Middle Aged
  • Prospective Studies

Substances

  • Interferons
  • Cyclic GMP